Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate Inhalation Powder

**Semantic type:** Pharmacologic Substance

**Definition:** An inhalation powder formulation composed of a fixed combination of the furoate salt form of the glucocorticoid fluticasone, the bromide salt form of the muscarinic receptor antagonist umeclidinium, and the triphenylacetate salt form of the long-acting beta-2 adrenergic agonist vilanterol, with anti-inflammatory and bronchodilator activities. Upon oral inhalation of the fluticasone furoate/umeclidinium bromide/vilanterol trifenatate inhalation powder via an inhaler, fluticasone binds to intracellular glucocorticoid receptors (GRs), exhibiting inhibitory activities against multiple cell types and mediators associated with inflammation. Umeclidinium antagonizes M3 muscarinic receptors located on smooth muscle cells, thereby preventing smooth muscle contraction and resulting in bronchodilation. Vilanterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells.

**Synonyms:** - Fluticasone Furoate-Umeclidinium Bromide-Vilanterol Trifenatate Inhalation - Fluticasone Furoate-Umeclidinium Bromide-Vilanterol Trifenatate Inhalation Powder - Fluticasone-Umeclidinium-Vilanterol Inhalation Powder - Fluticasone/Umeclidinium/Vilanterol Inhalation Powder - Trelegy Ellipta